Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 3.7%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index fell by 3.0% [1] - The CSI Innovative Drug Industry Index declined by 1.9%, and the CSI Biotechnology Theme Index dropped by 1.6% [1][5] - The CSI 300 Pharmaceutical and Health Index saw a decrease of 0.8% [1][12] Group 2 - The Hang Seng Innovative Drug ETF (159316) experienced a net subscription of 21 million units in half a day, with over 1 billion yuan attracted in the month, ranking first among similar products [1] - The index focuses on leading stocks in the Hong Kong medical and health industry, consisting of 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other healthcare sectors [3] - The Innovative Drug ETF tracks the CSI Innovative Drug Industry Index, which includes no more than 50 companies primarily engaged in innovative drug research and development [5]
资金逆势加码创新药，恒生创新药ETF月内净流入超10亿元，位居同类产品第一
Sou Hu Cai Jing·2025-10-23 05:21